FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Thursday

 

Aphios Awarded Grant for cGMP Manufacturing of CBD from Marijuana for Multiple Sclerosis and Other CNS Disorders



























September 15, 2015 08:00 AM Eastern Daylight Time

WOBURN, Mass.--(BUSINESS WIRE)--Aphios Corporation today announced that it has been awarded Phase II of a Fast Track SBIR grant from the National Institute on Drug Abuse (NIDA), NIH for manufacturing cannabidiol (CBD) from marijuana following current Good Manufacturing Practices (cGMP) for Multiple Sclerosis and other central nervous system (CNS) disorders.

The primary goal of this research program is to develop a process for manufacturing pharmaceutical grade CBD following cGMP of the US FDA for use in clinical trials for Multiple Sclerosis and other CNS disorders by the NIH, Aphios and other researchers. The availability of pharmaceutical-grade CBD and other cannabinoids such as Δ9-THC and CBG, manufactured following cGMP guidelines, will facilitate clinical evaluation by investigators and researchers on MS, childhood epilepsy, and other CNS disorders such as Parkinson’s disease (PD), Alzheimer’s disease (AD), Traumatic Brain Injury (TBI), Post-Traumatic Stress Disorder (PTSD), addiction and glaucoma.

According to Dr. Trevor P. Castor, CEO and Principal Investigator on this grant, “Marijuana, which contains more than 100 cannabinoids, has been used anecdotally for centuries for diverse medical indications. There have been numerous self-reported cases by patients that smoking marijuana alleviates symptomatology, some of which has been confirmed by numerous studies and surveys. Research suggests that some cannabinoids and analogs have potential therapeutic benefits. We thus have indications that both cannabinoids from nature and our endogenous ‘endocannabinoids’ are valuable products and targets for treating some CNS disorders. The cGMP manufacturing of clinical-grade, natural non-psychotropic cannabinoids from marijuana that impact CNS disorders is significant because it will establish safety and efficacy of standardized, non-psychotropic cannabinoids through rigorous clinical trials, providing benefits to thousands of patients.”

About Aphios Corporation

Aphios is an emerging growth, green biotechnology company using environmentally sustainable technologies to improve drug discovery, manufacturing, delivery and safety, and develop therapeutics for the treatment of cancers and supportive care, infectious diseases such as HIV, and CNS disorders such as Alzheimer’s disease, Parkinson’s disease and Multiple Sclerosis.

Research reported in this press release is supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number R44DA038932. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Contacts
Aphios Corporation
Trevor P. Castor, Ph.D., CEO, 001 781-932-6933
tcastor@aphios.com

Story Source: The above story is based on materials provided by BUSINESSWIRE
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News